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MFG-E8 Downregulates IL-17 Expression in Sepsis by 
Modulating STAT3 Activation
Cindy Cen, MD1, Monowar Aziz, PhD1,2, Weng-Lang Yang, PhD1,2, Jeffrey Nicastro, MD1, 
Gene F. Coppa, MD1, and Ping Wang, MD1,2
1Department of Surgery, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY
2Center for Translational Research, The Feinstein Institute for Medical Research, Manhasset, NY
Abstract
Background—Milk fat globule-epidermal growth factor-factor VIII (MFG-E8) is a secretory 
glycoprotein with a known role in inflammation. In sepsis, interleukin-17 (IL-17) acts as a 
proinflammatory cytokine to exaggerate systemic inflammation. We hypothesize that MFG-E8 
downregulates IL-17 expression in sepsis.
Methods—Sepsis was induced in 8-week-old male C57BL/6 mice by cecal ligation and puncture 
(CLP). Recombinant mouse MFG-E8 (rmMFG-E8) at a dosage of 20 μg/kg body weight or PBS 
was concurrently injected. After 10 h, blood and spleen samples were harvested for analysis. For 
in vitro studies, splenocytes isolated from healthy mice pre-treated with rmMFG-E8 and 
splenocytes from MFG-E8 knockout (mfge8−/−) mice were stimulated with phorbol myristate 
acetate (PMA) and ionomycin, followed by measurement of IL-17 expression with either qPCR or 
ELISA.
Results—At 10 h after CLP, rmMFG-E8 inhibited the elevated levels of IL-17 protein in serum 
by 31%, compared to the vehicle. In the spleen, rmMFG-E8 reduced the upregulated IL-17 mRNA 
and protein levels by 81% and 51%, respectively. This correlated with a significant reduction in 
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organ injury markers AST and ALT in sepsis after administration of rmMFG-E8. In vitro 
treatment of splenocytes isolated from healthy mice with rmMFG-E8 showed significant 
downregulation in PMA/ionomycin-induced IL-17 expression. In contrast, CD4 T-cells from 
mfge8−/− mice showed significant upregulation of IL-17 compared to wild-type mice. The 
phosphorylated level of STAT3 was downregulated in spleen tissue of septic mice treated with 
rmMFG-E8. Conversely, mfge8−/− mice showed increased pSTAT3 compared to wild-type mice 
after sepsis.
Conclusion—Our findings demonstrate MFG-E8-mediated downregulation of IL-17 expression, 
implicating its potential as a novel therapeutic agent against sepsis.
INTRODUCTION
Sepsis is a pervasive and constant human health concern that affects approximately 3 million 
people in the United States every year 1, 2. Mortality is estimated between 15 % and 30%, at 
a cost to our healthcare system for hospital care totaling more than $24 billion each year 2–4. 
Injury from sepsis occurs as a result of an exaggerated or uncontrolled inflammatory 
response and mortality stems from injuries sustained by the various organ systems.
Interleukin-17 (IL-17) is a family of cytokines first found to be expressed in activated CD4 
T- cells, and includes IL-17A, -B, -C, -D, -E, and -F 5–7. They were initially thought to only 
be produced from Th17 cells, but later found to be produced in other immune cells including 
neutrophils, lymphocytes, inducible Natural Killer T (iNKT) cells, γδ T cells, and Paneth 
cells 5, 6, 8. IL-17A has been linked to severity of inflammation in tissues, and seen to 
predominantly interact with endothelial cells, epithelial cells, fibroblasts, and macrophages, 
producing proinflammatory mediators such as IL-1β, IL-6, and tumor necrosis factor-α 
(TNF-α) 5. IL-17 is involved in varied processes that include bacterial defense, rheumatoid 
arthritis, allograft rejection, tumor modulation, and asthma and allergic reactions 9. 
Although it is in these latter autoimmune processes that IL-17 has been more widely studied, 
IL-17 has recently attracted attention as a regulator of innate immunity in host defense.
Regulation of IL-17 expression in activated T-cells is mediated via a wide range of 
cytokines, including IL-23, transforming growth factor-β1 (TGF-β1), IL-6, IL-1β, and 
IL-21 6, 10. Differentiation of IL-17-producing Th17 cells requires a novel set of 
transcription factors, including signal transducer and activator of transcription 3 (STAT3), 
retinoic acid receptor related orphan receptor γ (RORγ), and nuclear factor kappa B (NF-
κB) 6, 10. Conversely, IL-10 is well known for suppressing IL-17 expression in Th17 cells 
and macrophages 11. Mice deficient in IL-10 will exhibit higher levels of IL-17 due to 
STAT3 and RORγ upregulation 11. Similarly, IL-18, an IL-1 family epithelial-derived 
cytokine, has recently been shown to regulate IL-17 expression during homeostatic and 
inflammatory conditions likely by antagonizing IL-1R1 signaling in Th17 cells 12.
In an experimental model of sepsis using cecal ligation and puncture (CLP), IL-17 was 
identified to promote high levels of proinflammatory mediators and bacteremia 9. Levels of 
IL-17 rose in a time-dependent manner after CLP, and in vitro incubation of macrophages 
with lipopolysaccharide (LPS) and IL-17 increased production of TNF-α, IL-1β, and IL-6 9. 
Furthermore, targeting of IL-17 with neutralizing antibodies showed a protective effect, with 
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reduced bacteremia and increased survival 9. Additionally, neutralization of peritoneal IL-17 
after CLP resulted in markedly improved neutrophil infiltration and decreased levels of 
proinflammatory cytokines 13.
We have previously shown that administering recombinant milk fat globule-EGF factor VIII 
(MFG-E8) during sepsis provides beneficial effects 14, 15. MFG-E8 is a 66 kDa glycoprotein 
that is expressed in nearly all organs and various cell types that include macrophages and 
dendritic cells 16. It is strongly expressed in mammary glands, as well as in the spleen, 
lungs, liver, lymph nodes, and brain 17, 18. It was initially identified as a major component of 
mouse milk fat and is known to play a role in facilitating the phagocytic clearance of 
apoptotic cells by professional phagocytes 16, 17. MFG-E8 is secreted from cells and binds to 
αvβ3-integrin on phagocytes and exposed phosphatidylserine (PS) on apoptotic cells via its 
N- and C-terminal conserved domains, respectively, enhancing phagocytic engulfment of 
dead cells 16, 17. Apart from this universal function, a direct, MFG-E8-mediated anti-
inflammatory role via inhibition of pro-inflammatory cytokines and chemokines has recently 
been reported 19, 20. Hence, MFG-E8 is pivotal for maintaining tissue homeostasis by 
regulating several cell signaling events, and its deficiency can lead to severe inflammatory 
disorders 17, 18, 21, 22. Although beneficial outcomes of MFG-E8 treatment in sepsis and in 
other inflammatory disorders have been demonstrated, its molecular mechanism has yet to 
be fully elucidated. In this study, we investigated the role of MFG-E8 in decreasing the pro-
inflammatory cytokine, IL-17 in sepsis. Based on our findings, MFG-E8 could serve as a 
therapeutic agent in sepsis by reducing IL-17 expression both locally and systemically.
MATERIALS AND METHODS
Animal model of sepsis
Male 8–10 weeks old C57BL/6 mice (21–28 g) purchased from Taconic (Albany, NY, USA) 
were anesthetized with isofluorane and underwent cecal ligation and puncture (CLP) 23. 
Briefly, a 1.5 cm incision was made to the abdominal wall, and the cecum exposed and 
ligated 0.5 cm from the tip with 4-0 silk suture. A 22-gauge needle was used to make two 
punctures through and through to the distal cecum, extruding a small amount of fecal 
material. The cecum was replaced into the abdominal cavity, and the abdomen was closed in 
two layers with running 6-0 nylon suture. The sham mice underwent the same procedure 
with the exception that the cecum was neither ligated nor punctured. Animals were 
resuscitated with 1 ml of normal saline subcutaneously.
In vivo administration of recombinant mouse MFG-E8 (rmMFG-E8)
Immediately after performing CLP, a small incision on the neck was made to expose the 
internal jugular vein (IJ). Commercially available recombinant mouse MFG-E8 (rmMFG-
E8) (Cat. No.: 2805-MF-050; R&D systems, Minneapolis, MN) was delivered by bolus 
injection through the IJ vein using 29G × 1/2″ U-100 insulin syringe (Terumo Medical 
Corporation, Elkton, MD) at a concentration of 20 μg/kg BW in 100 μl or same volume of 
PBS as vehicle. A survival study performed with this model in mice determined the lethal 
dose (LD50) to occur at day 7 in the 10 day monitoring period 24. The proximal and distal 
ends of the jugular vein were ligated and the wound was closed with one interrupted 4-0 
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nylon suture. After wound closure, the mouse was given 500 μl of normal saline (NS) 
subcutaneous fluid resuscitation. The animals were allowed food and water ad libitum until 
10 hours after the time of intervention and the animals were euthanized. Blood and tissue 
samples were collected for various ex vivo analyses. All experiments were performed in 
accordance with the guidelines for the use of experimental animals by the National Institute 
of Health and were approved by the Institutional Animal Care and Use Committee of The 
Feinstein Institute for Medical Research.
Quantitative real-time PCR analysis
Total RNA was extracted from spleen tissue using TRIzol (Invitrogen; Carlsbad, CA) and 
reverse-transcribed into cDNA using murine leukemia virus reverse transcriptase (Applied 
Biosystems; Foster City, CA). The PCR reaction was performed in 25 μl of final volume 
containing 0.08 μmol of forward and reverse primer, cDNA, and 12.5 μl SYBR Green PCR 
Master Mix (Applied Biosystems). The thermal profile used by the Applied Biosystems 
7300 real-time PCR machine was: 50°C for 2 min, 95°C for 10 min, 45 cycles of 95°C for 
15 seconds, and 60°C for 1 min. Mouse β-actin was used for normalization. Relative 
expression of mRNA was represented as fold change in comparison to the sham group. The 
primer sequences are: IL-17A (NM_010552): Forward: CAGGGAGAGCTTCATCTGTGT, 
Reverse: AGGAAGTCCTTGGCCTCAGT; β-actin (NM_007393): Forward: 
CGTGAAAAGATGACCCAGATCA, Reverse: TGGTACGACCAGAGGCATACAG.
Western blot analysis
Spleen tissue was homogenized in lysis buffer (10 mM Tris-HCl, pH 7.5; 120 mM NaCl; 
1% NP-40; 1% sodium deoxycholate; and 0.1% sodium dodecyl sulfate) containing protease 
inhibitor (Roche Diagnostics; Indianapolis, IN), then sonicated (Fisher Scientific; Waltham, 
MA). Protein concentrations were determined by Bio-Rad protein assay reagent (Hercules, 
CA). Total lysate was electrophoresed on SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes. The membranes were then blocked with 0.1% casein in 0.2× PBS 
and then incubated with anti-IL-17A (Cat. No. ab79056; Abcam, Cambridge, MA), 
phosphorylated STAT3 (Tyr705) (Cat. No.: 9131; Cell Signaling Technology, Beverly, 
MA), or β-actin (Cat. No.: A2228; Sigma, St. Louis, MO) primary antibodies. After 
washing, the membranes were incubated with a fluorescently-labeled secondary antibody 
(Cat. No.: 925-68020, 925-32211, LI-COR; Lincoln, NE). The Odyssey image system (LI-
COR) was used to scan the membranes, and the Odyssey densitometric software used to 
measure band intensities.
Analysis of organ injury markers
Blood samples were centrifuged at 2,000g for 15 min to collect serum and then either 
analyzed for injury parameters immediately, or stored at −80°C. Aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) levels were 
measured using assay kits from Pointe Scientific (Canton, MI).
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In vitro splenocyte and CD4 T-cell isolation and stimulation
For in vitro studies, the spleen was removed from normal C57BL/6 mice and cell 
suspensions were prepared by disruption using frosted glass slides in RPMI medium with 
10% FBS. The isolated cell suspensions were then passed through a 70 μm nylon mesh (BD 
Falcon, Durham, NC), and red blood cell (RBC) lysis was conducted with RBC lysis 
solution (10 mM KHCO3, 150 mM NH4Cl, 0.1 mM EDTA, pH 8.0). After centrifugation at 
200g for 10 min, the cell pellets were resuspended in RPMI medium with 10% FBS. A total 
of 2.5 × 106 splenocytes were plated and pre-treated with either rmMFG-E8 (500 ng/ml) or 
PBS for 90 min. The cells were then stimulated with Phorbol 12-myristate 13-acetate (PMA) 
and ionomycin at 10 ng/ml and 1 μg/ml, respectively. After 5 h of PMA/ionomycin 
stimulation, cells were collected by centrifugation at 300g followed by mRNA isolation and 
cDNA preparation for the measurement of IL-17A expression by qPCR.
In another in vitro study, a total of 1 × 106 CD4 T-cells/ml isolated from wild-type (wt) and 
MFG-E8 knockout (mfge8−/−) mice spleens using mouse EasySep CD4 T-cell isolation kit 
(Stem Cell Technologies, Vancouver, Canada) were stimulated by PMA (10 ng/ml) and 
ionomycin (1 μg/ml) overnight, followed by the measurement of IL-17 levels in culture 
supernatants by enzyme linked immunosorbent assay (ELISA) (eBioscience; San Diego, 
CA). Mfge8−/− mice were obtained as a kind gift from Dr. Shigekazu Nagata, Kyoto 
University, Japan. They were developed by replacing exons 4–6 of the MFG-E8 gene with a 
neomycin cassette. The chimera mice were then backcrossed to C57BL/6 mice at least 9 
times to generate mfge8−/− mice 25.
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM) and compared via one way 
analysis of variance (ANOVA) and Dunn’s and Student-Newman-Keuls (SNK) test for 
multiple group comparisons. Student’s t-test and Mann Whitney Rank Sum test were applied 
only for a pair comparison. Significance was considered if p ≤ 0.05 between the 
experimental groups.
RESULTS
Recombinant MFG-E8 downregulates IL-17A levels in blood after CLP
IL-17 serves as a pro-inflammatory cytokine and its expression is induced in sepsis 5, 9. To 
assess the in vivo effect of rmMFG-E8 on IL-17A production after CLP, serum was 
analyzed by western blot. As shown in Figure 1, septic mice treated with vehicle showed a 
35% increase in IL-17. Mice treated with intrajugular rmMFG-E8 had significantly 
decreased levels of IL-17A protein in the plasma, with approximately 31% inhibition 
compared to the vehicle-injected animals.
Downregulation of IL-17A expression in spleen tissue after recombinant MFG-E8 
administration into septic animals
The spleen is a major organ for IL-17 expression. In addition to systemic levels of IL-17A, 
we wanted to examine local expression. In septic mice, vehicle spleen exhibited a 17-fold 
and 68% increase in mRNA and protein expression, respectively, compared to sham. 
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Compared to the vehicle group, intrajugular treatment of rmMFG-E8 significantly inhibited 
IL-17A mRNA and protein expression by 81% and 51%, respectively (Figure 2A, B).
Recombinant MFG-E8 attenuates organ injury in sepsis
Sepsis causes severe organ injury as reflected by the elevated levels of AST and ALT in 
serum. To establish whether rmMFG-E8 has any protective effect against the severity of 
sepsis, we performed CLP on C57BL/6 mice and treated them with rmMFG-E8 or vehicle 
via intrajugular injection. We then assessed the levels of AST, ALT, and LDH in serum at 
10 h after CLP. We found that after sepsis the serum levels of AST, ALT, and LDH were 
significantly upregulated 2.2-fold, 2.9-fold, and 2.5-fold respectively (Figure 3A–C). In 
contrast, mice treated by rmMFG-E8 significantly downregulated serum AST and ALT 
levels by 39% and 43%, respectively, compared to the vehicle-treated CLP animals (Figure 
3A, B). For LDH, although we could not attain statistically significance, a considerable 
inhibition of about 24% in its levels was evident in rmMFG-E8-treated mice as compared to 
that of vehicle-treated septic mice (Figure 3C).
In vitro treatment of recombinant MFG-E8 directly attenuates IL-17A expression in 
splenocytes
To evaluate the direct effects of rmMFG-E8, we established an in vitro system. Primary 
splenocyes were pre-treated with rmMFG-E8 and then stimulated using PMA/ionomycin, 
followed by the assessment of IL-17A expression. PMA and ionomycin are both naturally 
isolated compounds that are commonly used together to stimulate intracellular cytokine 
production. As shown in Figure 4, in vitro treatment of rmMFG-E8 in splenocytes 
significantly downregulated IL-17A expression at its mRNA level by 49% as compared with 
the PBS-treated counterpart.
Deficiency of endogenous MFG-E8 leads to exaggerated IL-17 expression in vitro
To examine whether MFG-E8 deficiency causes increased IL-17 expression, we cultured 
CD4 T-cells isolated from wt or mfge8−/− mice in the presence of PMA/ionomycin and then 
assessed IL-17 production in culture supernatants. Of note, we observed significant 
upregulation of IL-17 production 4.7-fold from the CD4 T-cells of mfge8−/− mice compared 
to wt mice, indicating that loss of MFG-E8 might potentiate IL-17 production during 
inflammation (Figure 5).
Activation of STAT3 in the spleen is attenuated in recombinant MFG-E8-treated septic 
animals
To investigate the underlying mechanism of rmMFG-E8-mediated downregulation of IL-17 
expression in sepsis, we focused on phosphorylated STAT3 (pSTAT3), a vital transcription 
factor for IL-17 expression. Septic animals showed a 4.7-fold increase in level of IL-17 
expression in spleen tissue compared to the sham. Animals treated with rmMFG-E8 showed 
a 54% inhibition of STAT3 phosphorylation in spleen tissue (Figure 6A).
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STAT3 phosphorylation in the spleen is increased in mfge8−/− mice after CLP
To further confirm the role of MFG-E8 in regulating STAT3 in sepsis, we induced CLP in 
mfge8−/− mice and analyzed spleen tissue for pSTAT3. As shown in Figure 6B, there is 
significant upregulation of pSTAT3 levels in both wt and mfge8−/− mice after CLP as 
compared to their respective sham animals, 2.7-fold and 4.8-fold, respectively. There is also 
a 25% increase in the level of pSTAT3 protein between the wt and mfge8−/− mice. Together 
with Figure 6A, these data support the notion that inhibition of IL-17 expression by 
rmMFG-E8 in sepsis is mediated through the downregulation of STAT3 activation.
DISCUSSION
Sepsis is a major clinical problem and a significant burden on resources in our intensive care 
units. Even though various treatment modalities have been implicated in reducing sepsis-
related mortality, none have been successful. There has only been one FDA-approved 
treatment available on the market, recombinant activated protein C, drotrecogin alfa (Eli 
Lilly, Indianapolis, IN), but it was withdrawn due to concerns about safety and questions 
about efficacy 26. Clinical trials have also been conducted with the aim to counteract 
individual sepsis-inducing inflammatory mediators—for example, tumor necrosis factor 
(TNF)-α and interleukin (IL)-1 27. Unfortunately, none of the trials demonstrated any 
benefit from treatment 28. Attention has therefore shifted toward targeting novel cytokines 
that regulate other pro-inflammatory molecules in response to invading pathogens 29, 30. 
IL-17 is an example of a pleiotropic cytokine that interacts with macrophages, epithelial 
cells, fibroblasts, and endothelial cells and can initiate production of a wide range of 
proinflammatory mediators such as IL-1, TNF-α, IL-6, and IL-8. The strategy of 
neutralizing IL-17 is therefore a distinct approach from previous experiments with IL-1 and 
TNF-α blockade/inhibitors.
Originally identified as an important factor for clearance of apoptotic cells, MFG-E8 has 
been shown to be beneficial in sepsis 15, 25, 31, 32. It has a role in diverse physiological 
functions, including anti-inflammation, tissue regeneration, and clearance of apoptotic cells 
to maintain tissue homeostasis, which makes it an important component in various acute and 
chronic inflammatory diseases 18. Another protein that also serves as a bridging molecule 
for the phagocytosis of apoptotic cells, growth arrest-specific protein 6 (GAS6), has been 
shown to downregulate IL-17 in serum and spleen, and be protective in sepsis 33, 34. IL-17 is 
known to cause exaggerated inflammation and organ injury during the course of 
inflammatory disease, and strategies for targeting IL-17 during experimental sepsis in 
rodents were found to be beneficial 5, 6, 9, 35. Direct blockade of IL-17 with intravenously 
administered antibody, even at 12 h after a severe model of CLP, improved survival and 
decreased systemic proinflammatory mediators and bacteremia 9. Similarly, injection with 
anti-IL-17A antibody into the peritoneal cavity of septic mice also showed a survival 
advantage 13. In our previous studies, we have shown a significant improvement in survival 
with administration of recombinant MFG-E8 in septic rats 32. We have also shown that 
mfge8−/− mice had significantly increased mortality compared to wild-type mice after 
CLP 24. It is therefore reasonable to explore the potential function of MFG-E8 as another 
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scavenging molecule for apoptotic clearance in the downregulation of IL-17 production in 
sepsis.
For our model, since other studies have shown that serum levels of IL-17 reached its peak at 
around 12 h after CLP, we chose to evaluate the efficacy of rmMFG-E8 for regulating IL-17 
expression at 10 h, which is close to the above time point 9, 13. IL-17 levels could also peak 
as early as 3 h after CLP, occuring in a case of a more severe model 36. Our study revealed 
that there is inhibition of IL-17A expression in blood and spleen tissue of septic mice treated 
with rmMFG-E8, and also direct attenuation of IL-17 expression under in vitro conditions. 
The outcome of rmMFG-E8-mediated downregulation of IL-17 expression strongly 
correlated with decreased levels of organ injury markers. We established a novel link 
between MFG-E8 and IL-17 expression during sepsis, and also focused on a new paradigm 
for exploring a potential role towards controlling the innate immune system.
Our experimental model did not include the use of antibiotics since we were studying the 
animals for only a short period of time after non-severe CLP. All the mice survived at time 
of harvest at 10 h, though some appeared sick. These mice had severe systemic 
inflammation, as shown by elevated levels of pro-inflammatory cytokine IL-17 and injury 
markers, ALT, AST, and LDH. Since our current study does not evaluate for survival after 
CLP, but instead involves a non-lethal model of CLP to study the pathogenesis of sepsis, we 
did not pursue an antibiotic treatment approach.
Male mice were chosen for our experiments instead of mixed gender mice because of recent 
findings from experimental and clinical studies indicating sex-specific differences in sepsis 
and infectious disease 37. Male and female sex steroids exhibit immune-modulating 
functions in both humoral and cell-mediated immune responses under normal conditions and 
in varied disease processes 37. Experimental studies in mice revealed a significantly 
increased survival rate of proestrus female mice following polymicrobial sepsis induced by 
CLP compared with male animals 38. Therefore, male and female sex differences may not be 
ignored when using animals to study sepsis pathogenesis. To generate reliable and consistent 
findings, we only used male mice. Furthermore, specific to the purposes of our study, MFG-
E8 is a milk-derived glycoprotein that is abundantly expressed and secreted from the 
mammary gland of female mice 18. Studies show that the hormone prolactin can induce 
MFG-E8 expression during the lactation period of female mice 39, which would be difficult 
to adequately control for in an experiment with mixed gender mice.
Aside from sepsis, MFG-E8 has also been studied in other processes. An indirect role of 
MFG-E8 for regulating IL-17 expression has previously been shown in a model for tumor 
growth 40. Granulocyte-macrophage colony-stimulating factor (GM-CSF) upregulates MFG-
E8 via macrophage expression. GM-CSF-deficient macrophages were shown to have 
markedly decreased MFG-E8 levels in the spleen, lung, and other tissues, which resulted in 
an altered immune cell and cytokine profile 40. Co-culturing GM-CSF deficient 
macrophages with naïve T-cells in the presence of apoptotic cells resulted in Th17 skewing 
due to impaired phagocytosis of apoptotic cells caused by reduced expression of MFG-
E8 40.
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Even in chronic inflammatory disease, MFG-E8 deficiency is correlated with increased 
IL-17 levels. In a model of periodontitis, loss of MFG-E8 led to increased bone loss which 
was associated with elevated levels of IL-17 from excised gingival tissues 41. Similarly, in a 
study of an MFG-E8 homolog, Del-1, periodontitis was accompanied by a decrease in Del-1 
expression, and associated with an increase in neutrophil infiltration and increased IL-17 
expression 42. Knockout mice for Del-1 also showed an increased level of IL-17A and 
neutrophils specifically in the lung 42.
The mechanism of IL-17 expression and its functions have been extensively studied in 
recent years 6, 7. STAT3 serves as a potent transcription factor for the expression of a wide 
range of pro-inflammatory genes 43. Activated STAT3 has been well reported as a vital 
transcription factor for the expression of IL-17 44. STAT3 is phosphorylated at Tyr705 
which allows dimerization and translocation to the nucleus as a transcription factor to induce 
target gene expression 45. To ascertain a mechanistic pathway for IL-17A upregulation, we 
focused on assessing STAT3 activation in terms of Tyr705 phosphorylation and noticed 
significantly decreased levels of STAT3 phosphorylation in the spleen of rmMFG-E8-
treated mice after sepsis. Although the role of MFG-E8 for regulating STAT3 activation was 
previously demonstrated in an in vitro system utilizing peritoneal macrophages, its clinical 
relevancy was unknown 19. In our model of acute systemic inflammation, we discovered the 
negative regulatory role of MFG-E8 for downregulating IL-17 expression in serum and 
tissue, and relationship to reducing organ injury markers. Further studies could reveal the 
missing novel negative regulators that might control STAT3 activation upon MFG-E8 
treatment.
Apart from the deleterious role of IL-17, there are also some studies that suggest that 
IL-17A could be beneficial to the host in sepsis. Studies by Ogiku et al showed that 
mortality in sepsis was increased among IL-17 knock-out mice compared to their wt 
counterparts 46. Similarly, in other studies involving CLP or K. pneumonia/T. gondii-
mediated acute inflammatory models, IL-17 receptor (IL-17R) deficient mice had reduced 
survival due to reduced neutrophil chemotaxis at the infectious foci to clear the bacterial 
load 47, 48. These findings reflect the importance of IL-17/IL-17R axis in host defense 
against infection. Obviously, as a component of the innate immune system, IL-17 and its 
receptor might be upregulated at a desired level to carry out their designated roles in 
responding to infection. Loss of expression of IL-17 or IL-17R with knockout mice might 
not be beneficial due to this impaired response against infection. Therefore, a fine-tuned 
balance should be emphasized for both host protection and also regulation of the abnormal 
induction seen in the septic “cytokine storm.”
In summary, our study revealed the inhibition of IL-17A expression in blood and spleen 
tissue in mice treated with rmMFG-E8 after sepsis, and direct attenuation of IL-17 
expression under in vitro conditions. This downregulation of IL-17 expression strongly 
correlated with decreased levels of organ injury markers. Therefore, there is a clearly 
beneficial role of MFG-E8 in downregulating IL-17 expression via modulating STAT3 
activation, implicating its potential as a novel therapeutic agent against sepsis.
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LIST OF ABBREVIATIONS
CLP cecal ligation and puncture
BW body weight
PBS phosphate-buffered saline
AST aspartate aminotransferase
ALT alanine aminotransferase
LDH lactate dehydrogenase
SEM standard error of the mean
SNK Student-Newman-Keuls
STAT3 signal transducer and activator of transcription 3
pSTAT3 phosphorylated STAT3
MFG-E8 milk fat globule-epidermal growth factor-factor VIII
rmMFG-E8 recombinant murine MFG-E8
IL interleukin
PMA phorbol 12-myristate 13-acetate
PMN polymorphonuclear neutrophil
GM-CSF granulocyte-macrophage colony-stimulating factor
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Figure 1. IL-17 expression in blood after sepsis and effect of rmMFG-E8
After 10 h of sepsis, serum was collected from sham, vehicle-, and rmMFG-E8-treated 
animals. A total of 3 μl of serum from each group was analyzed via western blot. Ponceau 
staining confirmed equal loading. Compared to the vehicle group, intrajugular treatment of 
rmMFG-E8 at a dose of 20 μg/kg BW inhibited IL-17 protein levels in the plasma by 31%. 
Sham, n=3 mice; vehicle-, and rmMFG-E8-treated, n=6 mice/group. Data are expressed as 
mean ± SEM and compared by one-way ANOVA by SNK method (*p<0.05 vs. sham; # 
p<0.05 vs. vehicle).
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Figure 2. Effect of rmMFG-E8 on IL-17 expression in the spleen
Spleen tissue was isolated from sham, vehicle- and rmMFG-E8-treated animals after 10 h of 
sepsis. Extracted mRNA and protein were subjected to real-time PCR and western blot to 
determine IL-17 expression at its transcriptional and translational levels, respectively. 
Compared to the vehicle, intrajugular treatment of rmMFG-E8 at 20 μg/kg BW inhibited 
IL-17 (A) mRNA, and (B) protein expression by 81% and 51%, respectively. Sham, 
vehicle-, and rmMFG-E8-treated, n=4–8 mice/group. For both real-time PCR and western 
blot, the results are normalized with β-actin as an internal control and equal loading control 
for respective experiments. The results are expressed as fold induction in comparison with 
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the sham. Data are expressed as mean ± SEM and compared by one-way ANOVA by SNK 
method and Student’s t test (*p<0.05 vs. sham; # p<0.05 vs. vehicle).
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Figure 3. Treatment with recombinant mouse MFG-E8 attenuates organ injury
Serum was collected at 10 h after CLP from sham, vehicle-, and rmMFG-E8-treated (20 
μg/kg BW) mice. Levels of (A) AST (B) ALT, and (C) LDH were measured and found to be 
reduced in the treatment group. Sham, n=3 mice; vehicle-, and rmMFG-E8-treated, n=7 
mice/group. Data are expressed as means ± SEM and compared by one-way ANOVA by 
Dunn’s and SNK method, and Mann Whitney Rank Sum test (*p<0.05 vs. sham; # p<0.05 
vs. vehicle).
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Figure 4. In vitro treatment of rmMFG-E8 in splenocytes decreases PMA/ionomycin-induced 
IL-17 production
Splenocytes were isolated from C57BL/6 mice and a total of 1.5 × 106 cells/ml in a 24-well 
culture plate were pre-treated with rmMFG-E8 (500 ng/ml) for 90 min, followed by 
stimulation with PMA (10 ng/ml) and ionomycin (1 μg/ml) for 5 h. mRNA was then 
extracted for real-time PCR to quantify IL-17 expression. IL-17 mRNA expression is 
significantly decreased by 49% with rmMFG-E8 treatment. The ratio obtained in the PBS 
control was arbitrarily set to 1. The results are obtained from n=3 mice/group with 3 
independent experiments. β-actin serves as an internal control for normalization of the 
results. Data are expressed as mean ± SEM and compared by one-way ANOVA by SNK 
method (*p<0.05 vs. sham; # p<0.05 vs. vehicle).
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Figure 5. In vitro stimulation with PMA/ionomycin shows increased IL-17 production in CD4 T-
cells isolated from MFG-E8 deficient mice
CD4 T-cells from 8–10 week-old male wt or mfge8−/− mice spleens were isolated by 
negative selection. A total of 1.5 × 106 cells/ml isolated from wt or mfge8−/− mice in a 24-
well culture plate were stimulated by PMA (10 ng/ml) and ionomycin (1 μg/ml) for 5 h, 
followed by the assessment of IL-17 in culture supernatants by ELISA. Cells from mfge8−/− 
mice exhibited 4.7-fold upregulation of PMA/ionomycin-induced IL-17 production 
compared to that of wt mice. The results are obtained from n=4 mice/group. Data are 
expressed as mean ± SEM and compared by one-way ANOVA by SNK method and 
Student’s t test (*p<0.05 vs. sham; # p<0.05 vs. vehicle).
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Figure 6. Treatment of rmMFG-E8 into the septic animals downregulates STAT3 
phosphorylation in the spleen
(A) Vehicle or rmMFG-E8 (20 μg/kg BW) was injected intravenously into the CLP animals. 
Following 10 h of CLP, spleen samples were harvested to analyze for phosphorylation of 
STAT3 by western blot. Mice treated with rmMFG-E8 downregulated STAT3 
phosphorylation in spleen tissue by 54%. (B) Sepsis was induced in C57BL/6 wt and 
mfge8−/− mice by CLP and after 10 h spleen tissue was collected for western blot. Mfge8−/− 
mice showed significantly increased levels of pSTAT3 by 25% compared to wt mice. The 
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representative results for 6A are obtained from sham, n=5 mice; vehicle and rmMFG-E8 
treatment, n=6–7 mice/group. The representative results for 6B are obtained from sham, n=3 
mice; wt and mfge8−/−, n=5 mice/group. Results are normalized with β-actin as an equal 
loading control and are expressed as fold induction in comparison with the sham. Data are 
expressed as mean ± SEM and compared by one-way ANOVA by SNK method(*p<0.05 vs. 
sham; # p<0.05 vs. vehicle).
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